AstraZeneca plc, GlaxoSmithKline plc And The Future Of Pharma

Thinking of investing in AstraZeneca plc (LON: AZN) or GlaxoSmithKline (LON: GSK)? Then read this article.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The drugs industry used to be very simple. Companies would invest money in research to develop the next blockbuster drug. Patent protection would mean that these new drugs would provide a steady flow of income to Big Pharma. Much of the increased profit would then be spent on more research. And so we had the virtuous circle of increasing profits and increasing share prices that sustained the industry for years.

Big Pharma must be more creative

But about a decade ago, people started to realise that most of the low-hanging fruit had already been picked. In the 1980s stomach acid treatment Zantac was the best selling drug in the world. Around 2000, Losec was an even bigger seller. But nothing is ever linear. The follow-up medicines to these winners could simply not match their sales.

After all, if a doctor already has a treatment that cures the ailment without side effects, why should he or she spend more on a more recent drug that’s little different? That’s particularly so when the doctor is already familiar with the current medicine and it will soon be off-patent.

This means that Big Pharma is having to be far more creative about how it will generate its profits in coming years.

Today, there are still blockbuster drugs, but they’re biological rather than chemical medicines, based on antibody technologies that are now at the cutting edge of medical science. These treatments are providing step change improvements in diseases such as cancer and arthritis, and they’re a particular strength of AstraZeneca (LSE: AZN).

Adapt and survive

But most firms are finding that they have ageing pharmaceutical portfolios and many of their medicines will be branded and over-the-counter. Here profits will be generated by the quantity sold, rather than by margins. This is an approach that suits companies such as GlaxoSmithKline (LSE: GSK), with its broad portfolio of treatments.

And then there are emerging markets. This is where much of the growth will be as the ever-increasing middle classes of China, India and other emerging markets start to spend much more of their wealth on healthcare. The growing population of this world, and its increasing wealth, means that there will always be a market for the products that AstraZeneca and GlaxoSmithKline make. But we will see a shift in the mix, from the premium end to mass-market and budget treatments.

So the future of pharma is more complex than you might think. It’s no longer a linear game, but more a battle on many fronts. Medical research is advancing very fast. The pharmaceutical industry needs to adapt to advancing science, and a new, rapidly growing market with different priorities and different needs.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Prabhat Sakya has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca and GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Arrow symbol glowing amid black arrow symbols on black background.
Investing Articles

£5,000 of 9.2%-yielding Legal & General shares could make me £599 a month in passive income over time!

Legal and General shares remain a top passive income stock in my core portfolio holdings, with a 9.2% yield and…

Read more »

Investing Articles

With a 10.4% yield, P/E ratio of 9.9, and a P/B of 0.37, is this FTSE 100 stock a no-brainer buy for me?

Using a range of popular valuation measures, this FTSE 100 stock appears to offer tremendous value for money. So is…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Down nearly 18% from its 52-week high, is the Lloyds share price now a screaming buy for me?

In recent weeks, the Lloyds share price has under-performed the wider market. Could this be the buying opportunity that I’m…

Read more »

Investing Articles

As BAE Systems’ share price drops 14% should I buy more?

FTSE 100 defence giant BAE Systems recently reiterated strong growth guidance, leaving its share price looking significantly undervalued to me.

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

After an 18% jump on its 2024 results, is it too late for me to consider buying this FTSE 100 hidden gem?

This FTSE 100 technology firm unveiled very strong 2024 results recently and a big share buyback, but is it too…

Read more »

Investing Articles

£5,000 invested in Rolls-Royce shares in 2023 would have made this much by now

Rolls-Royce shares have been one of the best-performing UK FTSE 100 investments over the last two years. But how much…

Read more »

Young Asian woman holding a cup of takeaway coffee and folders containing paperwork, on her way into the office
Investing Articles

£5,000 invested in Lloyds shares in 2023 would be worth this much now

Lloyds shares and other banking stocks have thrived in 2024, but has it been a good investment for shareholders who…

Read more »

Burst your bubble thumbtack and balloon background
Investing Articles

Why are investors blowing a raspberry at this FTSE 250 stock?

After a successful IPO, the share price of this FTSE 250 stock's fallen. Our writer looks at the reasons and…

Read more »